176 related articles for article (PubMed ID: 18193691)
21. [Calcium antagonists: current and future applications based on new evidence. Calcium channel blockers and autonomic nervous system].
Hirooka Y; Sunagawa K
Clin Calcium; 2010 Jan; 20(1):32-7. PubMed ID: 20048431
[TBL] [Abstract][Full Text] [Related]
22. Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients.
Kondo T; Goto R; Sonoda K; Yasuda T; Ono K; Takaki Y; Yatsuda R; Miyamura N; Araki E
Intern Med; 2010; 49(7):637-43. PubMed ID: 20371952
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension.
Inomata J; Murai H; Kaneko S; Hamaoka T; Ikeda T; Kobayashi D; Usui S; Furusho H; Sugiyama Y; Takata S; Takamura M
J Hypertens; 2014 Sep; 32(9):1898-904. PubMed ID: 24979307
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
[TBL] [Abstract][Full Text] [Related]
25. Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure.
Ohmura C; Watada H; Shimizu T; Sakai K; Uchino H; Fujitani Y; Kanazawa A; Hirose T; Kawamori R
Endocr J; 2007 Dec; 54(5):805-11. PubMed ID: 17895576
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy of efonidipine hydrochloride, a T-type calcium channel inhibitor, on sympathetic activities.
Harada K; Nomura M; Nishikado A; Uehara K; Nakaya Y; Ito S
Circ J; 2003 Feb; 67(2):139-45. PubMed ID: 12547996
[TBL] [Abstract][Full Text] [Related]
27. Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Koide H; Ueda Y; Takeuchi M; Yamagishi S
Clin Cardiol; 2011 Jun; 34(6):372-7. PubMed ID: 21432860
[TBL] [Abstract][Full Text] [Related]
28. Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
Nakamura K; Yamagishi S; Inoue H
Med Hypotheses; 2005; 65(1):155-7. PubMed ID: 15893134
[TBL] [Abstract][Full Text] [Related]
29. Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo university (ALPS-J).
Miyauchi K; Kojima T; Yokoyama T; Kurata T; Yokoyama K; Kawamura M; Suwa S; Okazaki S; Inoue K; Fujiwara Y; Sumiyoshi M; Tanimoto K; Nakazato Y; Yamagami S; Daida H
Cardiovasc Drugs Ther; 2009 Oct; 23(5):409-13. PubMed ID: 19763803
[TBL] [Abstract][Full Text] [Related]
30. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
[TBL] [Abstract][Full Text] [Related]
31. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure.
Kuramoto K; Ichikawa S; Hirai A; Kanada S; Nakachi T; Ogihara T
Hypertens Res; 2003 Mar; 26(3):201-8. PubMed ID: 12675275
[TBL] [Abstract][Full Text] [Related]
32. Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine.
Fujisawa M; Yorikane R; Chiba S; Koike H
J Cardiovasc Pharmacol; 2009 Apr; 53(4):325-32. PubMed ID: 19295444
[TBL] [Abstract][Full Text] [Related]
33. Azelnidipine.
Wellington K; Scott LJ
Drugs; 2003; 63(23):2613-21; discussion 2623-4. PubMed ID: 14636080
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory effects of azelnidipine tablets on morning hypertension.
Kario K; Sato Y; Shirayama M; Takahashi M; Shiosakai K; Hiramatsu K; Komiya M; Shimada K
Drugs R D; 2013 Mar; 13(1):63-73. PubMed ID: 23512719
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
Shinohara K; Hirooka Y; Ogawa K; Kishi T; Yasukawa K; Utsumi H; Sunagawa K
Clin Exp Hypertens; 2012; 34(6):456-62. PubMed ID: 22471901
[TBL] [Abstract][Full Text] [Related]
36. Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy.
Motoki H; Koyama J; Izawa A; Tomita T; Miyashita Y; Takahashi M; Ikeda U
Echocardiography; 2014 Nov; 31(10):1230-8. PubMed ID: 24645985
[TBL] [Abstract][Full Text] [Related]
37. Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats.
Nakamoto M; Ohya Y; Sakima A; Yamazato M; Takishita S
Hypertens Res; 2007 Apr; 30(4):359-66. PubMed ID: 17541215
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis.
Yamamoto E; Lai ZF; Yamashita T; Tanaka T; Kataoka K; Tokutomi Y; Ito T; Ogawa H; Kim-Mitsuyama S
J Hypertens; 2006 Oct; 24(10):2057-69. PubMed ID: 16957567
[TBL] [Abstract][Full Text] [Related]
39. Effects of azelnidipine on uric acid metabolism in patients with essential hypertension.
Miyazaki S; Hamada T; Hirata S; Ohtahara A; Mizuta E; Yamamoto Y; Kuwabara M; Nosaka Y; Igawa O; Ogino K; Kato M; Yoshida A; Ninomiya H; Cheng J; Moriwaki Y; Yamamoto K; Hisatome I
Clin Exp Hypertens; 2014; 36(7):447-53. PubMed ID: 24433018
[TBL] [Abstract][Full Text] [Related]
40. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
Kimura Y; Hirooka Y; Sagara Y; Sunagawa K
Clin Exp Hypertens; 2007 Jan; 29(1):13-21. PubMed ID: 17190727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
